483
GlaxoSmithKline dba Human Genome Sciences IncFDA 483 - GlaxoSmithKline dba Human Genome Sciences Inc - December 11, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Humon Genomics Sciences, Inc. in Rockville, MD, revealed significant deficiencies in their drug substance manufacturing processes. Observations included inadequate microbial control, ineffective root cause analysis and CAPA implementation, and failures in data integrity and training procedures. Additionally, the firm lacked appropriate identity testing for raw materials and adequate control over manufacturing components.
- Inspection Date
- December 11, 2023
- Product Type
- Biologics
Open in Dashboard
ID · 845ffa38-5805-4d93-95b8-ff8e8d207fcf